Equity Profile

SYRE

Spyre Therapeutics, Inc.

Health CareBiotechnology$6.4B

May5Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:00 AM EDT

Spyre Therapeutics Misses on EPS, Stock Up 2.72%

Metric	Actual	Expected	Surprise
EPS	$-0.74	$-0.65	-11.45%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Spyre Therapeutics Misses on EPS, Stock Up 2.72%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.74	$-0.65	-11.45%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

What It Means

Spyre Therapeutics reported a larger-than-expected loss per share, which may raise concerns among investors about its financial health. However, the stock rose by 2.72% following the announcement, indicating that investors may be optimistic about the company's future despite the miss on EPS. The lack of revenue and guidance adds uncertainty about the company's immediate prospects.

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the health care sector....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses.

-0.65

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the health care sector. With a market cap of $6 billion, it plays a crucial role in advancing medical treatments, particularly in areas with high unmet needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q4-2025, Spyre reported an EPS of -0.70, slightly worse than the expected -0.66. The stock reacted positively, gaining 3.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Spyre to report a loss this quarter, with an EPS consensus of -0.65. Investors will be closely watching for any signs of revenue generation or updates on drug development.

Bull Case

If Spyre can exceed EPS expectations and provide positive updates on its pipeline, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to future revenue, it could lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

-0.65

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Spyre's EPS come in better than the consensus estimate of -0.65?

A beat on EPS could indicate better-than-expected cost management and operational efficiency, which would be a positive signal for investors.

What updates will management provide regarding future revenue generation?

Any insights into upcoming partnerships or product launches could significantly impact investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Spyre's ability to manage costs effectively, leading to a better-than-expected EPS this quarter.

Supporting Evidence

Spyre has a history of beating EPS estimates, with a 63% beat rate in the last eight quarters.

The stock has shown resilience following earnings surprises, often reacting positively even after misses.

Key Risk

If the EPS comes in better than -0.65, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on how well Spyre manages its expenses and any potential developments in its product pipeline.

Bull Confirmed If

An EPS of -0.53 or better would confirm the bull case, indicating strong cost management.

Bear Confirmed If

An EPS of -0.81 or worse would confirm the bear case, suggesting ongoing challenges in operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±12.1%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±9.9% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

86.3%

Calls (11K)P/C Ratio: 1.89Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats EPS expectations, history suggests the stock could rise by around 1.18% on average the next day, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses EPS estimates, history suggests a potential decline of about 3.48%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on cost management strategies and their impact on EPS.
2Updates on the drug pipeline and potential revenue sources.
3Insights into partnerships or collaborations that could drive future growth.
4Management's outlook on market conditions and competitive landscape.
5Any changes in guidance or expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies in the health care sector....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses.

-0.65

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+8.20%

Avg Stock Reaction

-0.03%

Last Quarter Recap

In Q4-2025, Spyre reported an EPS of -0.70, slightly worse than the expected -0.66. The stock reacted positively, gaining 3.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Spyre to report a loss this quarter, with an EPS consensus of -0.65. Investors will be closely watching for any signs of revenue generation or updates on drug development.

Bull Case

If Spyre can exceed EPS expectations and provide positive updates on its pipeline, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to future revenue, it could lead to a sharp decline in stock price.

Key Metrics to Watch

EPS

-0.65

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses.

Revenue

While no revenue is expected this quarter, any updates on future revenue streams or partnerships could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Spyre's EPS come in better than the consensus estimate of -0.65?

A beat on EPS could indicate better-than-expected cost management and operational efficiency, which would be a positive signal for investors.

What updates will management provide regarding future revenue generation?

Any insights into upcoming partnerships or product launches could significantly impact investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Spyre's ability to manage costs effectively, leading to a better-than-expected EPS this quarter.

Supporting Evidence

Spyre has a history of beating EPS estimates, with a 63% beat rate in the last eight quarters.

The stock has shown resilience following earnings surprises, often reacting positively even after misses.

Key Risk

If the EPS comes in better than -0.65, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on how well Spyre manages its expenses and any potential developments in its product pipeline.

Bull Confirmed If

An EPS of -0.53 or better would confirm the bull case, indicating strong cost management.

Bear Confirmed If

An EPS of -0.81 or worse would confirm the bear case, suggesting ongoing challenges in operational efficiency.

Pre-Earnings Positioning

Options Market

Implied Move

±12.1%

Historical Avg

±3.1%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±9.9% while SYRE has averaged ±3.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

86.3%

Calls (11K)P/C Ratio: 1.89Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Spyre beats EPS expectations, history suggests the stock could rise by around 1.18% on average the next day, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.

Miss

If the company misses EPS estimates, history suggests a potential decline of about 3.48%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on cost management strategies and their impact on EPS.
2Updates on the drug pipeline and potential revenue sources.
3Insights into partnerships or collaborations that could drive future growth.
4Management's outlook on market conditions and competitive landscape.
5Any changes in guidance or expectations for the next quarter.